Key Metrics
11.95
Heat Index-
Impact LevelMedium
-
Scope LevelGlobal
-
Last Update2026-02-08
Key Impacts
Positive Impacts (8)
Eli Lilly and Co. (LLY)
Innovent Biologics (1801.HK)
Hang Seng Healthcare Index (HSHCI)
Chinese Biotech & Pharma Sector
Global CRO Sector
Contract Development & Manufacturing Organizations (CDMO) in China
Total impacts: 8 |
Positive: 8 |
Negative: 0
Event Overview
The partnership signifies a significant investment in the research and development of innovative drugs, emphasizing strategic collaboration for mutual financial and scientific benefits. The agreement includes substantial upfront and milestone payments, along with potential royalties, highlighting the commitment to advancing treatments in oncology and immunology.
Collect Records
信达生物与礼来公司达成肿瘤及免疫领域创新药物全球研发战略合作
2026-02-08 18:08
信达生物及其附属公司与礼来公司达成了一项战略合作，共同推进肿瘤及免疫领域创新药物的全球研发。根据协议，信达生物将获得3.5亿美元的首付款，并在达成特定里程碑后，有资格获得最高约85亿美元的额外付款。此外，信达生物还将根据大中华区以外的净销售额获得梯度销售分成。
Total records: 1